Chemotherapy is not generally useful for brain metastases, while second- and third-generation ALK inhibitors can penetrate the blood–brain barrier and treat brain metastases.[13] Ceritinib has been shown to have significant antitumor activity in patients with ALK+ NSCLC who have received prior crizotinib treatment.[2] Studies have shown that the median duration of response to ceritinib ranges from 7 to 12 months, and when used as a first-line therapy the mean PFS ranges from 16 to 25 months.[13–15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.